2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Papp K, Lebwohl M, Kircik L, Pariser D, Strober B, Krueger G, Berk D, Navale L, Higham R. The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. Dermatology And Therapy 2021, 11: 1079-1083. PMID: 34236691, PMCID: PMC8322185, DOI: 10.1007/s13555-021-00572-2.Peer-Reviewed Original Research
2017
Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Herrera V, McLeod L, Odom D, Elewski B. Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. Journal Of Psoriasis And Psoriatic Arthritis 2017, 2: 73-80. DOI: 10.1177/247553031700200206.Peer-Reviewed Original ResearchPsoriasis-related itchingWeek 12Disease severityBenefits of secukinumabInterleukin-17A antagonistSevere plaque psoriasisPatient-reported symptomsClinical trial dataDisease severity scoreQuality of lifeTraditional clinical measuresBackground PsoriasisPASI responseSecukinumab treatmentPlaque psoriasisComplete reliefSymptom reliefSeverity scoreClinical dataResponder statusClinical measuresGreater efficacyTrial dataSecukinumabTreatment effects